Evaluation of heterozygous deletion of TP53 gene in pleural fluid samples: A case series of 11 patients; [Plevral Sıvı Örneklerinde TP53 Geni Heterozigot Delesyonunun Değerlendirilmesi: 11 Hastalık Bir Seri]
| dc.contributor.author | Dirican N. | |
| dc.contributor.author | Bagci Ö. | |
| dc.contributor.author | Uz E. | |
| dc.contributor.author | Öztürk Ö. | |
| dc.contributor.author | Bircan H. | |
| dc.contributor.author | Dirican A. | |
| dc.date.accessioned | 2025-04-10T11:09:27Z | |
| dc.date.available | 2025-04-10T11:09:27Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | We described heterozygous deletion of tumor protein 53 (TP53) gene in 11 patients including 2 patients with non-malignant diseases (pneumonia) and 9 patients with malignant diseases [including small cell lung cancer (n = 3), non-small cell lung carcinoma (n = 4), non-Hodgkin’s lymphoma (n=1), and gastric carcinoma (n=1)]. Chromosomal aberrant status was analyzed by fluorescence in situ hybridization with centromere specific and 17p13.1 locus specific probes. In 3 of 9 cancer patients we did not find malignant pleural effusion with histological examination and/or closed pleural biopsy. Heterozygous deletion of TP53 gene was found to be significantly higher in patients with malignant disease when compared to the patients with benign pleural fluid. As a result, we suggest that heterozygous deletion of TP53 may have indicator value for malignancy; however further studies are warranted to confirm this suggestion in large patient cohorts. © 2016, Journal of Clinical and Analytical Medicine. All Rights Reserved. | |
| dc.identifier.DOI-ID | 10.4328/JCAM.4551 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/48745 | |
| dc.publisher | Derman Medical Publishing | |
| dc.title | Evaluation of heterozygous deletion of TP53 gene in pleural fluid samples: A case series of 11 patients; [Plevral Sıvı Örneklerinde TP53 Geni Heterozigot Delesyonunun Değerlendirilmesi: 11 Hastalık Bir Seri] | |
| dc.type | Article |